US News and World Report: Stem Cells May Hold the Fix
October 04, 2017
NEWS PROVIDED BY
Oct. 04, 2017
Believe it or not, the cure to what ails you could already be inside you. Welcome to the dawning world of stem cell therapy, in which researchers are exploring the possibilities of growing new body parts and healing old ones by using patients’ own stem cells. The idea is that these unspecialized cells (which can also be harvested from a donor) can be induced to develop into heart or lung or brain cells, say, and be injected to replace those damaged by disease or injury. While bone marrow stem cell therapies for certain cancers date back several decades, the approach is now being used or studied for a wide array of diseases and injuries.
“Stem cells could be the new antibiotics,” says Joshua Hare, director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine. “When you put the pieces of the puzzle together, stem cells could touch just about every area of medicine.”
For the record: The cells Hare is talking about are not taken from embryos, a practice mired in controversy. They come from an adult’s body tissue, usually the bone marrow, fat or skin. These “master cells” operate as a kind of internal repair system because they can replicate in a continuous fashion to replenish other cells or morph into cells with specialized functions.
Longeveron is researching treatments based on its Mesenchymal Stem Cells for a variety of aging-related diseases. In 2017, Longeveron published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its Mesenchymal Stem Cells in patients with Aging Frailty, a serious geriatric syndrome that can lead to other severe health conditions, such as heart disease. The company is now recruiting for an expanded Phase 2b Aging Frailty study.
Longeveron is also recruiting for a Phase 1 Alzheimer’s trial, and Phase 1 and 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients. Longeveron’s MSC product is derived from the bone marrow of young, healthy adult donors.
Longeveron () is a regenerative medicine therapy company founded in 2014. Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company’s research focus areas Aging Frailty, the Metabolic Syndrome and Alzheimer’s Disease and gratefully acknowledges the generous support of the National Institutes of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund. Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.
For more information about the clinical trials
Longeveron is sponsoring, visit ClinicalTrials.gov
or Longeveron’s website www.longeveron.com
SOURCE Longeveron LLC